NCT06075927View on ClinicalTrials.gov

Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

October 30, 2025

Conditions
CMV InfectionEBV InfectionStem Cell Transplant
Interventions
BIOLOGICAL

Virus specific T cells

"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2"

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT06075927 - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT | Biotech Hunter | Biotech Hunter